Trigger pSA predicting recurrence from positive choline PET/CT with prostate cancer after initial treatment

Area of Science:

• Nuclear medicine imaging
• Oncology
• Urology

Background:

• Biochemical recurrence of prostate cancer is a significant clinical challenge.
• Accurate detection of recurrent prostate cancer is essential for guiding treatment decisions.

Purpose of the Study:

• To evaluate the diagnostic performance of Choline positron emission tomography/computed tomography (PET/CT) in detecting recurrent prostate cancer.
• To determine the relationship between trigger prostate-specific antigen (PSA) levels and the accuracy of Choline PET/CT.

Main Methods:

• A meta-analysis was performed, synthesizing data from multiple studies.
• The diagnostic accuracy, including sensitivity and specificity, of Choline PET/CT was assessed.
• Detection rates for ¹⁸F-choline and ¹¹C-choline PET/CT were analyzed.

Main Results:

• Pooled sensitivity for choline PET/CT was 82% and specificity was 92%.
• ¹⁸F-choline PET/CT showed 81% sensitivity and 90% specificity; ¹¹C-choline PET/CT demonstrated 83% sensitivity and 92% specificity.
• The pooled detection rate for both ¹⁸F-choline and ¹¹C-choline PET/CT was 58%.

Conclusions:

• Trigger PSA level is a significant factor influencing Choline PET/CT findings in recurrent prostate cancer.
• The detection rate of Choline PET/CT for recurrent prostate cancer increases with rising PSA values.
• Choline PET/CT exhibits a higher detection rate when the trigger PSA level exceeds 2 ng/ml.